PEN Stock Analysis — Penumbra Inc.
Sector: Healthcare
AI Verdict
At 66.3x next year's earnings for just 8.4% EPS growth, you're paying a premium the numbers don't yet support—even with Penumbra's defensible hospital relationships and device innovation.
Competitive Moat
Penumbra specializes in minimally invasive devices for neuro and vascular interventions, with a defensible position built on proprietary catheter technologies and a strong clinical data portfolio supporting physician adoption. Its deep relationships with hospitals and ongoing innovation cycles make it difficult for new entrants to displace its products in critical care settings.
Summary
Penumbra stands out for its specialized neurovascular devices, but its valuation is stretched far above healthcare sector norms.
Where It Stands
Penumbra trades at 66.3x forward earnings—triple the healthcare sector median of 22x—despite analyst consensus for only 8.4% EPS growth next year.
Key Metrics
- Trailing P/E: 71.8x
- Forward P/E: 66.3x
- PEG Ratio: 8.58
- Earnings Growth: +0.1%
- Revenue Growth: +0.2%
- 52-Week High: $362.41
- 52-Week Low: $221.26
Analyst Consensus
8 Buy · 14 Hold · 0 Sell (22 analysts)
Bull Case
The company delivered 17.5% revenue growth YoY, indicating continued demand for its devices even at a premium valuation.
Bear Case
With a trailing PEG of 8.58, investors are paying over eight times what would be justified by its growth rate, leaving the stock highly vulnerable to any disappointment in execution.
Catalyst to Watch
Watch for clinical trial results or regulatory approvals that could materially accelerate EPS growth above the current 8.4% expectation.